Last updated: July 10, 2026
Executive summary: Infuvite Pediatric (pharmacy bulk package) is a pediatric multivitamin formulation product sold by Bausch Health (Bausch Health Companies Inc.). The investment case is driven less by novel drug IP and more by (1) whether the product has remaining regulatory exclusivity/Orange Book protection, (2) the likelihood of generic or private-label substitution for the bulk package and its specific NDC/labeling, and (3) supply and distribution durability in pediatric vitamin categories where pricing pressure is common. The available public record needed to map exact patent coverage and expiration dates tied to the pharmacy bulk package’s specific NDC strength/label is not present in the prompt, so a complete, decision-grade fundamentals and litigation/infringement risk assessment cannot be produced here.
What is Infuvite Pediatric pharmacy bulk package and who markets it?
Infuvite Pediatric is a pediatric multivitamin product used for nutritional supplementation in children. The phrase “pharmacy bulk package” typically indicates the product is distributed in a bulk container intended for pharmacy dispensing workflows (as opposed to unit-dose retail packaging). In market practice, pharmacy bulk presentations can change the competitive surface: substitution can occur at the NDC level, the label claim level, and sometimes the dispensing workflow level.
Market-relevant fundamentals (category-level):
- Pediatric vitamins are characterized by broad substitution, frequent retail churn, and price compression.
- Differentiation tends to be tied to formulation specifics (e.g., vitamin/mineral composition, excipients), pediatric dosing convenience, and payer/contracting behavior rather than high-barrier pharmaceutical IP.
Key investment implication: in this category, upside is usually limited unless the specific NDC has binding IP protection, persistent supply constraints, or contracting locks.
What patents protect Infuvite Pediatric pharmacy bulk package?
Featured-snippet answer: A patent landscape for Infuvite Pediatric depends on the exact active ingredients, strengths, dosage form, and NDC tied to the “pharmacy bulk package” listing. Patent coverage is assessed via the FDA Orange Book entries for the listed NDC(s), which map to formulation, method-of-use, and manufacturing patents.
Decision-grade requirement: the prompt does not provide the relevant NDC(s) or an Orange Book identifier for “Infuvite Pediatric (pharmacy bulk package),” so the patent protection question cannot be answered with the required precision (patent numbers, expiration dates, assignees, and claim scope).
How many patents cover the specific NDC and dosage form?
A defensible count requires:
- the Orange Book listing(s) for the product’s NDC,
- the attached patent(s),
- and the patent type (drug substance, drug product, method of use).
Without the NDC/Orange Book listing, the count would be speculative.
Which assignees hold the Infuvite Pediatric patents?
Assignee mapping requires the Orange Book patent links for the specific NDC and the underlying INPADOC/USPTO family. Those inputs are not in the prompt.
When does Infuvite Pediatric lose exclusivity or patent protection?
Featured-snippet answer: exclusivity and patent expiration are calculated from Orange Book listed exclusivity start and end dates and patent expiration dates for the relevant NDC.
This cannot be determined from the prompt because no NDC, Orange Book listing, or patent identifiers are provided.
Does the product have 5-year new chemical entity or 7-year orphan or other exclusivity?
Vitamins and nutritionals typically do not fit NCE/orphan exclusivity patterns, but some products can have:
- pediatric exclusivity extensions (6-month add-on),
- marketing exclusivity tied to formulation approvals,
- or regulatory exclusivity associated with specific applications.
A correct exclusivity assessment must be tied to the FDA approval pathway and Orange Book data for the exact NDC.
What is the Orange Book status of Infuvite Pediatric (pharmacy bulk package)?
Featured-snippet answer: Orange Book status is determined per NDC by listing category and patents with:
- Orange Book NDA holder,
- drug product code,
- and patent numbers.
The prompt does not include the Orange Book listing for the “pharmacy bulk package” NDC, so the Orange Book status cannot be reproduced accurately.
What generic entry risks exist for Infuvite Pediatric bulk packaging?
Featured-snippet answer: generic risk turns on whether the specific NDC is protected by Orange Book patents, whether it has exclusivity, and whether the sponsor’s labeling and formulation claims constrain substitution.
How fast could a competitor launch a substitute?
A generic or private-label entrant can move faster when:
- no relevant Orange Book patents block,
- labeling is broadly interchangeable,
- and the drug is not subject to complex method-of-use claims.
In pediatric vitamins, launch timing is also affected by:
- manufacturing capacity and ingredient sourcing,
- distribution channel contracts,
- and pharmacy formulary decisions.
A precise generic risk view requires Orange Book patent status and any relevant Paragraph IV litigation history, which cannot be extracted from the prompt.
Has there been patent litigation or Paragraph IV challenges for Infuvite Pediatric?
Featured-snippet answer: litigation risk requires docket-level data tied to:
- the Orange Book patents for the specific NDC,
- the challenger(s),
- and filing/settlement dates.
The prompt provides no NDC, Orange Book patents, or case identifiers. Without those, litigation mapping cannot be completed.
Which companies are challenging the product?
Cannot be determined without identifying the Orange Book listing and any court filings.
What settlement agreements exist and what are the agreed launch dates?
Settlement terms must be read from court dockets and/or public litigation summaries tied to specific patent challenges. The prompt provides no case record.
What formulations are protected by Infuvite Pediatric patents?
Formulation protection is usually covered under:
- drug product formulation patents (composition, excipients, dosage form),
- processes (manufacturing/encapsulation),
- stability and bioavailability-related claims (less typical for vitamins but possible for specific embodiments).
A formulation-specific protected-claims map requires patent numbers and claim language for the exact product/NDC.
How does Infuvite Pediatric compare with competing pediatric multivitamin drugs?
In pediatric vitamins, the main competitive axis is:
- ingredient composition (vitamin and mineral amounts),
- dosing regimen (drops/syrup/tablets),
- taste/matrix and excipient profile,
- availability and contracting,
- and total cost per dose.
A high-value comparison requires:
- the exact strengths and dosage form for the pharmacy bulk package,
- competitor NDCs or branded/generic product lists,
- and payer or channel pricing.
Those details are not provided in the prompt.
What is the revenue exposure and pricing power profile for Infuvite Pediatric?
Investment underwriting in this category should model:
- unit sales volume sensitivity to substitution,
- channel share and rebate/discount dynamics,
- ingredient cost pass-through,
- inventory turnover and supply reliability.
However, the prompt provides no:
- financials,
- segment reporting identifiers,
- pricing or unit data,
- or channel breakdown.
A decision-grade fundamentals analysis cannot be produced without those financial inputs and the specific product’s NDC-linked market footprint.
Manufacturing and IP barriers: what could block or delay generic competition?
For vitamins and multivitamin products, typical barriers include:
- formulation-specific manufacturing processes,
- stability requirements (shelf-life),
- supply chain constraints for key ingredient grades,
- and regulatory/quality documentation requirements.
A correct barrier assessment requires:
- the specific manufacturing process patents (if any),
- any FDA CMC-driven constraints tied to the labeled formulation,
- and the presence or absence of bottling/packaging proprietary steps.
No patent or CMC detail is supplied in the prompt.
Geographic coverage: does patent protection vary outside the US?
US exclusivity and patent status are the primary gating items for FDA generics. For non-US markets, protection depends on:
- national/regional patent filings,
- term extensions,
- and local regulatory exclusivity.
The prompt provides no jurisdictional filing list or family data for this product.
Investment scenario frameworks for Infuvite Pediatric: base, bull, bear
Base case (category-constrained branded durability):
- Branded product maintains share in pharmacy bulk channels.
- Generic/private label substitution increases gradually only where Orange Book/IP constraints are absent or weak.
Bull case (limited competition + protected NDC specifics):
- Orange Book shows enforceable patents or exclusivity tied to the exact pharmacy bulk package NDC.
- No easy formulation/design-around exists, and distribution contracts persist.
Bear case (NDC-level permissiveness + rapid substitution):
- Orange Book patents are absent or expiring with no meaningful continuation protection.
- Substitution at the NDC/label level accelerates, compressing pricing and margins.
This scenario split must be grounded in:
- the NDC Orange Book patent list,
- expiration timeline,
- and any litigation/settlement history.
Those inputs are missing.
Key Takeaways
- Infuvite Pediatric (pharmacy bulk package) sits in a pediatric multivitamin category where competitive substitution typically limits pricing power.
- The investment thesis hinges on product-specific Orange Book/NDC-level patent and exclusivity status and any associated litigation.
- The prompt does not provide the NDC(s) or Orange Book identifiers required to map patents, expiration dates, and legal risk.
- A decision-grade patent-and-timeline underwriting is not possible from the provided information.
FAQs
- How do I determine the exact Orange Book listing for “Infuvite Pediatric pharmacy bulk package”?
- What NDC-level factors dictate whether substitution is permitted for pediatric multivitamin pharmacy bulk packages?
- What patent types (formulation vs method-of-use vs manufacturing) typically matter most for pediatric nutritional products?
- How do Paragraph IV challenges work for non-prescription or nutritional-type products when an Orange Book listing exists?
- What market signals best predict price compression in pediatric vitamin products sold through pharmacy bulk channels?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
